159 related articles for article (PubMed ID: 21963870)
1. Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodies.
Pusic K; Xu H; Stridiron A; Aguilar Z; Wang A; Hui G
Vaccine; 2011 Nov; 29(48):8898-908. PubMed ID: 21963870
[TBL] [Abstract][Full Text] [Related]
2. Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine.
Pusic K; Aguilar Z; McLoughlin J; Kobuch S; Xu H; Tsang M; Wang A; Hui G
FASEB J; 2013 Mar; 27(3):1153-66. PubMed ID: 23195035
[TBL] [Abstract][Full Text] [Related]
3. Poly(I:C) adjuvant strongly enhances parasite-inhibitory antibodies and Th1 response against Plasmodium falciparum merozoite surface protein-1 (42-kDa fragment) in BALB/c mice.
Mehrizi AA; Rezvani N; Zakeri S; Gholami A; Babaeekhou L
Med Microbiol Immunol; 2018 Apr; 207(2):151-166. PubMed ID: 29397427
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
[TBL] [Abstract][Full Text] [Related]
5. Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1.
Douglas AD; de Cassan SC; Dicks MD; Gilbert SC; Hill AV; Draper SJ
Vaccine; 2010 Oct; 28(44):7167-78. PubMed ID: 20937436
[TBL] [Abstract][Full Text] [Related]
6. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.
Bargieri DY; Leite JA; Lopes SC; Sbrogio-Almeida ME; Braga CJ; Ferreira LC; Soares IS; Costa FT; Rodrigues MM
Vaccine; 2010 Apr; 28(16):2818-26. PubMed ID: 20170765
[TBL] [Abstract][Full Text] [Related]
7. Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.
Singh S; Miura K; Zhou H; Muratova O; Keegan B; Miles A; Martin LB; Saul AJ; Miller LH; Long CA
Infect Immun; 2006 Aug; 74(8):4573-80. PubMed ID: 16861644
[TBL] [Abstract][Full Text] [Related]
8. Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.
Otsyula N; Angov E; Bergmann-Leitner E; Koech M; Khan F; Bennett J; Otieno L; Cummings J; Andagalu B; Tosh D; Waitumbi J; Richie N; Shi M; Miller L; Otieno W; Otieno GA; Ware L; House B; Godeaux O; Dubois MC; Ogutu B; Ballou WR; Soisson L; Diggs C; Cohen J; Polhemus M; Heppner DG; Ockenhouse CF; Spring MD
Malar J; 2013 Jan; 12():29. PubMed ID: 23342996
[TBL] [Abstract][Full Text] [Related]
9. Biological activities of anti-merozoite surface protein-1 antibodies induced by adjuvant-assisted immunizations in mice with different immune gene knockouts.
Hui G; Choe D; Hashimoto C
Clin Vaccine Immunol; 2008 Aug; 15(8):1145-50. PubMed ID: 18562564
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and in vitro protective efficacy of recombinant Mycobacterium bovis bacille Calmette Guerin (rBCG) expressing the 19 kDa merozoite surface protein-1 (MSP-1(19)) antigen of Plasmodium falciparum.
Nurul AA; Norazmi MN
Parasitol Res; 2011 Apr; 108(4):887-97. PubMed ID: 21057812
[TBL] [Abstract][Full Text] [Related]
11. Pathways for potentiation of immunogenicity during adjuvant-assisted immunizations with Plasmodium falciparum major merozoite surface protein 1.
Hui GS; Hashimoto CN
Infect Immun; 1998 Nov; 66(11):5329-36. PubMed ID: 9784540
[TBL] [Abstract][Full Text] [Related]
12. A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodies.
Alaro JR; Partridge A; Miura K; Diouf A; Lopez AM; Angov E; Long CA; Burns JM
Infect Immun; 2013 Oct; 81(10):3843-54. PubMed ID: 23897613
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-1(42) using human compatible adjuvants.
Sachdeva S; Mohmmed A; Dasaradhi PV; Crabb BS; Katyal A; Malhotra P; Chauhan VS
Vaccine; 2006 Mar; 24(12):2007-16. PubMed ID: 16377036
[TBL] [Abstract][Full Text] [Related]
14. Impact of pre-existing MSP1(42)-allele specific immunity on potency of an erythrocytic Plasmodium falciparum vaccine.
Bergmann-Leitner ES; Duncan EH; Mease RM; Angov E
Malar J; 2012 Sep; 11():315. PubMed ID: 22958482
[TBL] [Abstract][Full Text] [Related]
15. Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.
Chitnis CE; Mukherjee P; Mehta S; Yazdani SS; Dhawan S; Shakri AR; Bhardwaj R; Gupta PK; Hans D; Mazumdar S; Singh B; Kumar S; Pandey G; Parulekar V; Imbault N; Shivyogi P; Godbole G; Mohan K; Leroy O; Singh K; Chauhan VS
PLoS One; 2015; 10(4):e0117820. PubMed ID: 25927360
[TBL] [Abstract][Full Text] [Related]
16. Purification, characterization, and immunogenicity of a disulfide cross-linked Plasmodium vivax vaccine candidate antigen, merozoite surface protein 1, expressed in Escherichia coli.
Dutta S; Ware LA; Barbosa A; Ockenhouse CF; Lanar DE
Infect Immun; 2001 Sep; 69(9):5464-70. PubMed ID: 11500418
[TBL] [Abstract][Full Text] [Related]
17. Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth.
Bruder JT; Stefaniak ME; Patterson NB; Chen P; Konovalova S; Limbach K; Campo JJ; Ettyreddy D; Li S; Dubovsky F; Richie TL; King CR; Long CA; Doolan DL
Vaccine; 2010 Apr; 28(18):3201-10. PubMed ID: 20188680
[TBL] [Abstract][Full Text] [Related]
18. Influence of HLA-DRB1 alleles on antibody responses to PfCP-2.9-immunized and naturally infected individuals.
Zhang Q; Xue X; Xu X; Wang C; Chang W; Pan W
J Clin Immunol; 2009 Jul; 29(4):454-60. PubMed ID: 19247821
[TBL] [Abstract][Full Text] [Related]
19. Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice.
Jeamwattanalert P; Mahakunkijcharoen Y; Kittigul L; Mahannop P; Pichyangkul S; Hirunpetcharat C
Clin Vaccine Immunol; 2007 Apr; 14(4):342-7. PubMed ID: 17314232
[TBL] [Abstract][Full Text] [Related]
20. The requirement of CD80, CD86, and ICAM-1 on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine.
Hui G; Hashimoto C
Vaccine; 2007 Dec; 25(51):8549-56. PubMed ID: 18006124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
